Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [921]

Where to next for the elderly with acute myeloid leukaemia?

Dr Uwe Platzbecker - University Hospital Dresden, Germany and Prof Gert...

Where to next for the elderly with acute myeloid leukaemia? ( Dr Uwe Platzbecker - University Hospital Dresden, Germany and Prof Gert Ossenkoppele - VU University Medical Center, Amsterdam, Netherlands )

New line of therapy for acute myeloid leukaemia

Dr David Taussig - Barts Cancer Institute, London, UK

New line of therapy for acute myeloid leukaemia ( Dr David Taussig - Barts Cancer Institute, London, UK )

Encouraging early results with GS-9973 for CLL and NHL

Dr Jeff Sharman- US Oncology, Eugene, Oregon

Encouraging early results with GS-9973 for CLL and NHL ( Dr Jeff Sharman- US Oncology, Eugene, Oregon )

Idelalisib and rituximab for previously treated chronic lymphocytic leukaemia...

Dr Richard Furman - New York Weill Cornell Medical Center, USA

Idelalisib and rituximab for previously treated chronic lymphocytic leukaemia (CLL) ( Dr Richard Furman - New York Weill Cornell Medical Center, USA )

Treating ALL patients with T cells targeted for CD19

Dr Laurence Cooper - MD Anderson Cancer Center, Houston, USA

Treating ALL patients with T cells targeted for CD19 ( Dr Laurence Cooper - MD Anderson Cancer Center, Houston, USA )

Chimeric antigen receptor produces complete responses and long-term persistence...

Dr. Stephen A. Grupp - University of Pennsylvania, Philadelphia, USA

$Chimeric antigen receptor produces complete responses and long-term persistence in children and adults relapsed, refractory ALL ( Dr. Stephen A. Grupp - University of Pennsylvania, Philadelphia, USA )$

Long-term functional persistence, B cell aplasia and anti-leukaemia efficacy in...

Dr Michael Kalos - University of Pennsylvania, Philadelphia, USA

$Long-term functional persistence, B cell aplasia and anti-leukaemia efficacy in refractory B cell malignancies ( Dr Michael Kalos - University of Pennsylvania, Philadelphia, USA )$

T cells engineered with chimeric antigen receptor targeting CD19 produce...

Dr Stephen A. Grupp - University of Pennsylvania, Philadelphia, USA

T cells engineered with chimeric antigen receptor targeting CD19 produce significant long-term persistence ( Dr Stephen A. Grupp - University of Pennsylvania, Philadelphia, USA )

Removal of alpha/beta T cells and of CD19 B cells in children With acute...

Dr Alice Bertaina - IRCCS Bambino Gesù Children's Hospital, Rome, Italy

Removal of alpha/beta T cells and of CD19 B cells in children With acute leukaemia ( Dr Alice Bertaina - IRCCS Bambino Gesù Children's Hospital, Rome, Italy )

Transplantation and short telomeres increase the risk of cognitive impairment

Dr Smita Bhatia - City of Hope National Medical Center, Duarte, California

Transplantation and short telomeres increase the risk of cognitive impairment ( Dr Smita Bhatia - City of Hope National Medical Center, Duarte, California )

Donor-derived anti-CD19 chimeric-antigen-receptor-expressing T cells cause...

Dr James Kochenderfer - National Cancer Institute, Bethesda, USA

Donor-derived anti-CD19 chimeric-antigen-receptor-expressing T cells cause regression of malignancy ( Dr James Kochenderfer - National Cancer Institute, Bethesda, USA )

Encouraging outcomes in older patients following nonmyeloablative...

Dr Yvette Kasamon - Johns Hopkins Kimmel Cancer Center, Baltimore, USA

Encouraging outcomes in older patients following nonmyeloablative haploidentical blood or marrow transplantation ( Dr Yvette Kasamon - Johns Hopkins Kimmel Cancer Center, Baltimore, USA )

More from ecancer